deferoxamine

The use of deferoxamine in the lavage solution is controversial.

Iron Poisoning 2010

Curry S, Bond R, Raschke R, et al. Fetal iron kinetics in a model of maternal iron poisoning with and without maternal deferoxamine therapy.

Iron Poisoning 2010

A one-year open label, non-comparative extension to a randomized, multicenter, phase II study to evaluate the safety, tolerability, pharmacokinetics and the effects on liver iron concentration of repeated doses of 5-30 mg/kg/day of ICL670 (deferasirox) relative to deferoxamine in sickle cell disease patients with transfusional hemosiderosis

Sickle cell disease research at The Children's Hospital 2010

Previously, only one medication, deferoxamine, was available for chelation.

Sickle cell disease research at The Children's Hospital 2010

A randomized, multicenter, phase II study to evaluate the safety and efficacy of oral ICL670 (deferasirox) 20 mg/kg/day relative to subcutaneous deferoxamine in sickle cell disease patients with iron overload from repeated blood transfusions

Sickle cell disease research at The Children's Hospital 2010

A deferoxamine challenge test can be given at a dose of 50 mg./kg.

Iron Poisoning 2010

In addition, iron induces lipid peroxidation generating reactive oxygen species (ROS), and deferoxamine, an iron chelator, has been shown to reduce edema after experimental ICH [53].

Recently Uploaded Slideshows 2009

Nonprogressive increases in serum creatinine have been noted in 38% of EXJADE-treated patients, compared to 14% of deferoxamine-treated patients in Study 1 and 36% vs 22%, respectively in Study 3, and appear to be dose related.

unknown title 2009

These commonly reported adverse events were predominantly mild to moderate in severity with serious adverse events reported in 9. 1% of patients in the EXJADE arm and 8. 6% of patients in the deferoxamine arm.

unknown title 2009

Until recently, from the age of 3 children suffering from thalassemia have had to take deferoxamine.

TODAY'S ZAMAN :: News 2009